Market Cap 104.27M
Revenue (ttm) 0.00
Net Income (ttm) -26.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 173,900
Avg Vol 480,464
Day's Range N/A - N/A
Shares Out 100.26M
Stochastic %K 41%
Beta 1.04
Analysts Strong Sell
Price Target $6.74

Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutan...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 289 910 0850
Fax: 905 481 2394
Address:
2265 Upper Middle Road East, Suite 602, Oakville, Canada
ElieoG
ElieoG Jan. 27 at 11:31 PM
$CRDL I follow around 300 stocks closely. I have been here for at least 4 years. Lets just say that 95% of the stocks i follow have either decreased in stock prices or are at the same level since 4 years. Crdl is just a typical title in the stock market. Everyone bashing on this stock should see the bigger picture and how the stock market works. Its not because you bought something, that you should expect to make an annuel progression of profit. its just a waiting game... Im guessing all the presidents from all these 300 companies i follow suck , have poor commication and so on, and dont care about the investors... ok.... sure...
0 · Reply
Rbyild
Rbyild Jan. 27 at 9:18 PM
$CRDL Only 164k shares traded. 😂 Where are those $20,000 pumper videos? 😂 Guess that simply taking a high dose of CBD for heart issues doesn’t seem to turn the crank of very many. After 5 years and multiple offerings / dilution, this turd is still struggling for relevance into western medicine. For the sake of all those suffering from Pericarditis , Myocarditis and HF. I certainly hope this is not another phase 3 failure by Elsley.
1 · Reply
Covode13
Covode13 Jan. 27 at 1:12 PM
$CRDL they needed the money to cover their pay raises lol
0 · Reply
Covode13
Covode13 Jan. 26 at 5:48 PM
$CRDL Below 1 again even with the investment haha what a turd. 💩
0 · Reply
Seb77
Seb77 Jan. 26 at 5:06 PM
$CRDL Added to my position again.✌️ Phase III (MAVERIC) is the real value driver — not PR. Phase II data were clean and clinically meaningful (pain, inflammation, recurrence). Cash runway into ~2028 — no biotech in distress here, and that matters. IP protection into ~2040 — heavily underestimated by the market. Orphan indication with potential broader use — a clearly asymmetric upside. From a scientific and strategic standpoint, the story remains intact. That said, we are paying with time: short term remains slow, frustrating😫
0 · Reply
Fastcapital
Fastcapital Jan. 26 at 12:02 PM
$CRDL Looks like the shorts are very busy typing today. Funny timing. While the noise picks up, the fundamentals keep improving: late-stage Phase 3 program, strong Phase 2 data, cash runway into 2028, patents into ~2040 and active talks with large biotech for partnerships. Low volume, but that’s usually what you see before broader recognition kicks in. I’ll focus on execution others can keep typing.
2 · Reply
mmtiddy
mmtiddy Jan. 26 at 11:43 AM
$CRDL I have shared the facts. The CEO stated they did not foresee any requirement to raise capital earlier than expected, emphasized comfort with the current cash position, and referenced partnering as a source of capital inflows. KEEP IN MIND, this interview was done right after the last dilution in late Q3 2025. To most investors, that clearly signals no near-term dilution. Completing a financing just four months later, resulting in roughly 10% dilution, directly contradicts the reasonable interpretation of that guidance. You can argue semantics, but from an investor communication standpoint, this was misleading. The interview did not convey urgency to dilute shareholders
0 · Reply
Covode13
Covode13 Jan. 26 at 10:51 AM
$CRDL David is a trash
0 · Reply
mmtiddy
mmtiddy Jan. 26 at 6:00 AM
$CRDL https://youtu.be/L6COcWUqAfM?si=CTocAkck9ofH5xKl @14:36 ”We don’t foresee any requirement to raise earlier than expected… the capital inflows to the company is from partnering initiatives… we are really comfortable with our current cash position that will fund a number of impactful corporate developments” 4 months later, he did an offering 🤭
4 · Reply
mmtiddy
mmtiddy Jan. 25 at 3:30 PM
$CRDL Each dilution raise just makes it harder for their shareholders to exit, this is gonna go down to red on Monday, they really played themselves saying we are well financed till 2027 and will not raise cash through dilution. But they lie as usual.
2 · Reply
Latest News on CRDL
ElieoG
ElieoG Jan. 27 at 11:31 PM
$CRDL I follow around 300 stocks closely. I have been here for at least 4 years. Lets just say that 95% of the stocks i follow have either decreased in stock prices or are at the same level since 4 years. Crdl is just a typical title in the stock market. Everyone bashing on this stock should see the bigger picture and how the stock market works. Its not because you bought something, that you should expect to make an annuel progression of profit. its just a waiting game... Im guessing all the presidents from all these 300 companies i follow suck , have poor commication and so on, and dont care about the investors... ok.... sure...
0 · Reply
Rbyild
Rbyild Jan. 27 at 9:18 PM
$CRDL Only 164k shares traded. 😂 Where are those $20,000 pumper videos? 😂 Guess that simply taking a high dose of CBD for heart issues doesn’t seem to turn the crank of very many. After 5 years and multiple offerings / dilution, this turd is still struggling for relevance into western medicine. For the sake of all those suffering from Pericarditis , Myocarditis and HF. I certainly hope this is not another phase 3 failure by Elsley.
1 · Reply
Covode13
Covode13 Jan. 27 at 1:12 PM
$CRDL they needed the money to cover their pay raises lol
0 · Reply
Covode13
Covode13 Jan. 26 at 5:48 PM
$CRDL Below 1 again even with the investment haha what a turd. 💩
0 · Reply
Seb77
Seb77 Jan. 26 at 5:06 PM
$CRDL Added to my position again.✌️ Phase III (MAVERIC) is the real value driver — not PR. Phase II data were clean and clinically meaningful (pain, inflammation, recurrence). Cash runway into ~2028 — no biotech in distress here, and that matters. IP protection into ~2040 — heavily underestimated by the market. Orphan indication with potential broader use — a clearly asymmetric upside. From a scientific and strategic standpoint, the story remains intact. That said, we are paying with time: short term remains slow, frustrating😫
0 · Reply
Fastcapital
Fastcapital Jan. 26 at 12:02 PM
$CRDL Looks like the shorts are very busy typing today. Funny timing. While the noise picks up, the fundamentals keep improving: late-stage Phase 3 program, strong Phase 2 data, cash runway into 2028, patents into ~2040 and active talks with large biotech for partnerships. Low volume, but that’s usually what you see before broader recognition kicks in. I’ll focus on execution others can keep typing.
2 · Reply
mmtiddy
mmtiddy Jan. 26 at 11:43 AM
$CRDL I have shared the facts. The CEO stated they did not foresee any requirement to raise capital earlier than expected, emphasized comfort with the current cash position, and referenced partnering as a source of capital inflows. KEEP IN MIND, this interview was done right after the last dilution in late Q3 2025. To most investors, that clearly signals no near-term dilution. Completing a financing just four months later, resulting in roughly 10% dilution, directly contradicts the reasonable interpretation of that guidance. You can argue semantics, but from an investor communication standpoint, this was misleading. The interview did not convey urgency to dilute shareholders
0 · Reply
Covode13
Covode13 Jan. 26 at 10:51 AM
$CRDL David is a trash
0 · Reply
mmtiddy
mmtiddy Jan. 26 at 6:00 AM
$CRDL https://youtu.be/L6COcWUqAfM?si=CTocAkck9ofH5xKl @14:36 ”We don’t foresee any requirement to raise earlier than expected… the capital inflows to the company is from partnering initiatives… we are really comfortable with our current cash position that will fund a number of impactful corporate developments” 4 months later, he did an offering 🤭
4 · Reply
mmtiddy
mmtiddy Jan. 25 at 3:30 PM
$CRDL Each dilution raise just makes it harder for their shareholders to exit, this is gonna go down to red on Monday, they really played themselves saying we are well financed till 2027 and will not raise cash through dilution. But they lie as usual.
2 · Reply
Covode13
Covode13 Jan. 24 at 8:50 PM
$CRDL nothing like making shares even more useless
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 23 at 10:24 PM
$CRDL Current Stock Price: $1.04 Contracts to trade: $2.5 CRDL Feb 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 43% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
1 · Reply
PDM21
PDM21 Jan. 23 at 2:44 PM
$CRDL so we are adding about 17m shares to the float, should put us around 122m fully diluted. Where are these “talks” with big pharma while they are watering down everyone’s money?
1 · Reply
newsfile_corp
newsfile_corp Jan. 23 at 2:17 PM
https://nfne.ws/281332 $CRDL $CRDL.TSX @cardiolrx #cannabidiol #CardiolRx #heartfailure #myocarditis #pericarditis #Biotechnology #Cannabis
1 · Reply
Covode13
Covode13 Jan. 22 at 11:34 PM
$CRDL still 💩
1 · Reply
ForTheBigGuy1
ForTheBigGuy1 Jan. 22 at 3:01 PM
0 · Reply
mmtiddy
mmtiddy Jan. 22 at 1:03 PM
$CRDL What this company needs is a good seekingalpha article from an analyst that has a respectable following
1 · Reply
PennyBLVD
PennyBLVD Jan. 22 at 11:51 AM
$CRDL does anyone know why this is showing Zero on here?
1 · Reply
peacetrain22
peacetrain22 Jan. 22 at 12:03 AM
$CRDL accumulation will start building well in advance of full participation in q2. Increased momentum in summer anticipating phase 3 readout
1 · Reply
Rbyild
Rbyild Jan. 21 at 7:55 PM
$CRDL As mentioned the other day I was going to dump the 25,000 shares I purchased last month @ .90 per share. One never goes broke taking profit, especially when there are plenty of other opportunities and this still having a long way to go, IMO. See ya all down the road. GLTA
1 · Reply
Covode13
Covode13 Jan. 20 at 8:56 PM
0 · Reply
SeanWav
SeanWav Jan. 20 at 8:07 PM
$CRDL 🚀🚀🚀🚀🚀🚀🚀
0 · Reply